MRNX was created on 2026-02-03 by Defiance. The fund's investment portfolio concentrates primarily on health care equity. MRNX seeks to deliver 2x leveraged exposure to the daily share price movement of Moderna, Inc. (NASDAQ: MRNA), net fees and expenses, through derivatives like swap agreements. MRNA develops mRNA-based vaccines and therapies, best known for its COVID-19 vaccine.